Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates
06:16pm, Wednesday, 26'th Feb 2025
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago.
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Wednesday, 26'th Feb 2025
YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 20
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Thursday, 20'th Feb 2025
DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
06:00am, Wednesday, 12'th Feb 2025
DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after marke
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Wednesday, 05'th Feb 2025
DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm ES
Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?
05:01am, Monday, 27'th Jan 2025
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
06:00am, Tuesday, 17'th Dec 2024
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meet
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 12'th Dec 2024
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Wednesday, 20'th Nov 2024
DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
12:30pm, Wednesday, 13'th Nov 2024
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript
10:46pm, Tuesday, 12'th Nov 2024
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Of
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
07:10pm, Tuesday, 12'th Nov 2024
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.01 per share a year ago.
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
04:05pm, Tuesday, 12'th Nov 2024
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versu
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
11:50am, Monday, 11'th Nov 2024
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
08:51am, Monday, 11'th Nov 2024
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
